MBRX logo

MBRX Moleculin Biotech, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$7.74
-0.19 (-2.40%)

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior th…

Market Cap: $7.89Mwww.moleculin.com

Price

No data yet.

Social Signal Score

52
5d
—
30d
53
2 mentions
—
60d
52
7 mentions
—
90d
52
11 mentions
—
news: 11

Analyst Ratings

4 analysts
Buyconsensus
Strong Buy 0Buy 4Hold 0Sell 0Strong Sell 0

Revenue

$0.00
$0.00
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-727.00
$-802.81–$-651.19
1 analysts
FY2026
$-56.63
$-58.28–$-54.98
2 analysts
FY2027
$-19.22
$-26.79–$-11.65
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Walter V. Klemp
Sector
Healthcare
Industry
Biotechnology
Employees
17
Beta
2.00
Country
US
Piotroski score
0 / 9 (Weak)
Altman Z-score
-16.67
www.moleculin.com